anti-Paraoxonase 1, mAb (17A12)

CHF 322.00
In stock
YIF-LF-MA0099100 µlCHF 322.00
More Information
Product Details
Synonyms PON; PON1; K-45; PON 1; EC=3.1.8.1; EC=3.1.1.2; EC=3.1.1.81; A-Esterase 1; Aromatic Esterase 1; Serum Aryldialkylphosphatase 1; Serum Paraoxonase/Arylesterase 1
Product Type Monoclonal Antibody
Properties
Clone 17A12
Isotype Mouse IgG1 κ
Immunogen/Antigen Recombinant human His-PON1 protein purified E. coli.
Application

Western Blot (1:500)

Crossreactivity Human
Mouse
Rat
Purity Detail Ammonium sulfate precipitation.
Formulation Liquid. HEPES with 0.15M NaCl, 0.01% BSA, 0.03% sodium azide, and 50% glycerol.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

Declaration Manufactured by AbFrontier
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Documents
MSDS No
Product Specification Sheet
Datasheet Download PDF

The paraoxonase(PON) gene-family in humans has three members, PON1, PON2, and PON3, aligned next to each other on the long arm of chromosome 7q21.3-22.1. PON1 of these is synthesized primarily in the liver and a portion is secreted into the plasma, where it is associated with high density lipoproteins (HDL). And It hydrolyzes the active metabolites of several other organophosphorus insecticides (e.g., chlorpyrifos oxon, diazoxon), as well as nerve agents such as sarin, soman and VX (lethal nerve agent). The PON1 polymorphism may be responsible for neurodegeneration and considered to be an independent risk factor for Parkinson’s disease. Hydrolyzes the toxic metabolites of a variety of organophosphorus insecticides. Capable of hydrolyzing a broad spectrum of organophosphate substrates and a number of aromatic carboxylic acid esters. May mediate an enzymatic protection of low density lipoproteins against oxidative modification and the consequent series of events leading to atheroma formation.

Product References

1) Akhmedova SN, et al. (2001) J Neurol Sci 184 (2):179-82. (General)
2) Kondo I, et al. (1998) Brain Res 806(2):271-3. (General)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.